Relay Therapeutics, Inc. Investing Cash Flow
Relay Therapeutics, Inc. (RLAY) reported Investing Cash Flow of -$320.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Relay Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$353.03M, a 569.79% decline year-over-year.
- Relay Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $32.90M, a 22.52% decline year-over-year.
- Relay Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $35.46M, a 22.29% increase year-over-year.
- Relay Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $39.73M.
- Relay Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $192.80M.
- Relay Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$41.08M, a 115.95% decline from fiscal 2023.
- Relay Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $257.63M.
- Relay Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$188.75M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$353.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$320.13M 10-Q · filed 2026-08-06 | -$284.66M derived: sum of 3 quarters · filed 2026-08-06 | -$244.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $32.90M 10-Q · filed 2026-05-05 | $68.36M derived: sum of 2 quarters · filed 2026-05-05 | $108.09M derived: sum of 3 quarters · filed 2026-05-05 | $183.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $35.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $75.19M derived: sum of 2 quarters · filed 2026-02-26 | $150.33M derived: sum of 3 quarters · filed 2026-08-06 | $192.80M 10-K · filed 2026-02-26 |
| 2025-09-30 | $39.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $114.87M derived: sum of 2 quarters · filed 2026-08-06 | $157.34M 10-Q · filed 2025-11-06 | $186.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $75.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $117.61M 10-Q · filed 2026-08-06 | $146.61M derived: sum of 3 quarters · filed 2026-08-06 | $20.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $42.47M 10-Q · filed 2026-05-05 | $71.46M derived: sum of 2 quarters · filed 2026-05-05 | -$54.70M derived: sum of 3 quarters · filed 2026-05-05 | -$9.15M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $29.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$97.16M derived: sum of 2 quarters · filed 2026-02-26 | -$51.61M derived: sum of 3 quarters · filed 2026-02-26 | -$41.08M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$126.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$80.61M derived: sum of 2 quarters · filed 2025-11-06 | -$70.08M 10-Q · filed 2025-11-06 | -$10.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $45.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $56.08M 10-Q · filed 2025-08-07 | $115.76M derived: sum of 3 quarters · filed 2026-02-26 | $187.12M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $10.53M 10-Q · filed 2025-05-05 | $70.21M derived: sum of 2 quarters · filed 2026-02-26 | $141.57M derived: sum of 3 quarters · filed 2026-02-26 | $192.85M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $59.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $131.04M derived: sum of 2 quarters · filed 2026-02-26 | $182.32M derived: sum of 3 quarters · filed 2026-02-26 | $257.63M 10-K · filed 2026-02-26 |
| 2023-09-30 | $71.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $122.64M derived: sum of 2 quarters · filed 2024-11-06 | $197.96M 10-Q · filed 2024-11-06 | $51.02M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $51.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $126.59M 10-Q · filed 2024-08-06 | -$20.34M derived: sum of 3 quarters · filed 2025-02-26 | $6.84M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $75.31M 10-Q · filed 2024-05-02 | -$71.62M derived: sum of 2 quarters · filed 2025-02-26 | -$44.44M derived: sum of 3 quarters · filed 2025-02-26 | -$1.05M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$146.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$119.75M derived: sum of 2 quarters · filed 2025-02-26 | -$76.36M derived: sum of 3 quarters · filed 2025-02-26 | -$188.75M 10-K · filed 2025-02-26 |
| 2022-09-30 | $27.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $70.58M derived: sum of 2 quarters · filed 2023-11-02 | -$41.81M 10-Q · filed 2023-11-02 | -$334.55M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $43.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$69.00M 10-Q · filed 2023-08-08 | -$361.74M derived: sum of 3 quarters · filed 2024-02-22 | -$340.95M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$112.38M 10-Q · filed 2023-05-04 | -$405.13M derived: sum of 2 quarters · filed 2024-02-22 | -$384.34M derived: sum of 3 quarters · filed 2024-02-22 | -$358.27M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$292.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$271.96M derived: sum of 2 quarters · filed 2024-02-22 | -$245.89M derived: sum of 3 quarters · filed 2024-02-22 | -$479.51M 10-K · filed 2024-02-22 |
| 2021-09-30 | $20.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $46.85M derived: sum of 2 quarters · filed 2022-11-03 | -$186.77M 10-Q · filed 2022-11-03 | -$263.19M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $26.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$207.55M 10-Q · filed 2022-08-04 | -$283.97M derived: sum of 3 quarters · filed 2023-02-23 | -$263.90M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$233.62M 10-Q · filed 2022-05-05 | -$310.04M derived: sum of 2 quarters · filed 2023-02-23 | -$289.97M derived: sum of 3 quarters · filed 2023-02-23 | -$202.32M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$76.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$56.35M derived: sum of 2 quarters · filed 2023-02-23 | $31.30M derived: sum of 3 quarters · filed 2023-02-23 | $81.67M 10-K · filed 2023-02-23 |
| 2020-09-30 | $20.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $107.72M derived: sum of 2 quarters · filed 2021-11-10 | $158.09M 10-Q · filed 2021-11-10 | $193.99M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $87.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $138.02M 10-Q · filed 2021-08-12 | $173.92M derived: sum of 3 quarters · filed 2022-02-24 | $180.99M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $50.37M 10-Q · filed 2021-05-13 | $86.27M derived: sum of 2 quarters · filed 2022-02-24 | $93.34M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $35.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $42.97M derived: sum of 2 quarters · filed 2022-02-24 | -$319.02M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $7.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$354.92M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$362.00M 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |